Hikma Pharmaceuticals USA
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$35.9M
Doctors Paid
11,850
Transactions
26,231
2024 Total
$942,317
Payment Breakdown by Category
Research$31.5M (87.7%)
Consulting$3.0M (8.4%)
Travel$521,705 (1.5%)
Food & Beverage$410,340 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $31.5M | 1,199 | 87.7% |
| Consulting Fee | $3.0M | 369 | 8.4% |
| Travel and Lodging | $521,705 | 261 | 1.5% |
| Food and Beverage | $410,340 | 21,934 | 1.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $202,544 | 45 | 0.6% |
| Honoraria | $145,300 | 59 | 0.4% |
| Education | $53,884 | 2,255 | 0.2% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $48,000 | 10 | 0.1% |
| Charitable Contribution | $30,000 | 2 | 0.1% |
| Gift | $3,906 | 97 | 0.0% |
Payments by Type
Research
$31.5M
1,199 transactions
General
$4.4M
25,032 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study | $16.9M | 2 | 682 |
| Epinephrine, 3.5mg, Dose Ranging, Fasted | $2.7M | 0 | 1 |
| Fluticasone / Salmeterol Powder, 100mcg/50mcg Multicenter Clinical Endpoint Study | $2.2M | 0 | 176 |
| Bedford NEMA Support | $1.4M | 0 | 18 |
| Morphine Pediatric Study | $1.2M | 0 | 88 |
| Comparative Five Groups, Randomized, Single Dose, Three-Treatment, Open Label Study to Evaluate the Dose Proportionality During Dose Escalation of 3.5 mg, 7 mg and 10.5 mg Epinephrine Nasal Spray and Using 0.3 mg EpiPen and 0.5 mg Adrenalin IM Injections as Positive Controls in Healthy Adults Under Fasting Conditions | $1.1M | 0 | 4 |
| Phase 1, Open-Label, Randomized, Three-Way Crossover, Comparative Bioavailability Study of Epinephrine Nasal Spray and Epinephrine Intramuscular Injection (0.5 mg Adrenalin) and Epinephrine Injection (0.3 mg) in Healthy Adults with Seasonal Allergies | $997,890 | 0 | 7 |
| Mercaptopurine, 20MG, Fasted Pivotal | $865,801 | 0 | 1 |
| Opioid / BTOD REMS | $746,778 | 0 | 20 |
| Phenobarbital Neonate Study Phase III | $618,752 | 0 | 21 |
| CLOAK | $600,721 | 0 | 16 |
| "A Pivotal, Single-Dose, Open-Label, Randomized, Two-Sequence, Full Replicate Bioavailability Study of Epinephrine Nasal Spray 7 mg and Adrenalin 0.5 mg (Epinephrine Intramuscular Injection) with an Add-On Comparator Arm of Epinephrine Injection, 0.3 mg in Healthy Adults" | $567,168 | 0 | 2 |
| A Single-Dose, Four-Period, Two-Treatment, Full Replicate Bioequivalence Study of Mercaptopurine 20 mg/mL suspension compared to PURIXAN 20 mg/mL suspension | $311,813 | 0 | 1 |
| Efficacy and Safety of Intra. Phenobarbital in Neonatal Seizures | $298,894 | 0 | 25 |
| Phase 4 Open Label Pediatric Study to Determine Pharmacokinetics of Phenylephrine | $264,163 | 1 | 69 |
| Vigabatrin Tablets, 500 mg, Fed Pilot Study | $157,311 | 0 | 1 |
| Vigabatrin Tablets, 500 mg, Fasted Pivotal Study | $157,311 | 0 | 1 |
| A Phase 1, Single-Dose, Open-Label, Randomized, Crossover, Pharmacokinetic Study of Epinephrine Nasal Spray and Epinephrine Intramuscular Injection (0.3 mg EpiPen and 0.5 mg Adrenalin) in Healthy Adults | $145,587 | 0 | 1 |
| Study to Assess the Efficacy and Safety of Intra. Phenobarbital in Neonatal Seizures | $124,059 | 0 | 6 |
| Opioid PMR Study | $14,222 | 2 | 37 |
| A Single-Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Erlotinib Hydrochloride 100 mg Tablets under Fasted Conditions | $1,102 | 0 | 1 |
| Antiretroviral Pregnancy Registry | $964.35 | 1 | 20 |
| A Single-Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Vigabatrin Tablets, 500 mg Compared to Sabril Tablets, 500 mg, under Fasted Conditions | $536.40 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Paul Hogya, M.d, M.D | Emergency Medicine | South Lebanon, OH | $396,943 | $0 |
| Mr. Warren Pleskow, Md, MD | Internal Medicine | Encinitas, CA | $296,553 | $0 |
| Elias Jabbour, M.d, M.D | Hematology & Oncology | Houston, TX | $235,510 | $0 |
| Hagop Kantarjian, Md, MD | Medical Oncology | Houston, TX | $98,428 | $0 |
| Ralph Defronzo, Md, MD | Endocrinology, Diabetes & Metabolism | San Antonio, TX | $66,846 | $0 |
| David Deyhimy, M.d, M.D | Addiction Medicine | Laguna Hills, CA | $59,097 | $0 |
| Tapan Kadia, M.d, M.D | Internal Medicine | Houston, TX | $58,104 | $0 |
| Dr. Naval Daver, Mbbs, MBBS | Hematology & Oncology | Houston, TX | $43,574 | $0 |
| Rami Komrokji, M.d, M.D | Hematology | Tampa, FL | $43,434 | $0 |
| Nuhad Ibrahim, M.d, M.D | Medical Oncology | Houston, TX | $34,986 | $0 |
| Rachid Baz, Md, MD | Hematology & Oncology | Tampa, FL | $29,285 | $0 |
| Farhad Ravandi-Kashani, M.d, M.D | Hematology & Oncology | Houston, TX | $28,613 | $0 |
| Vamsidhar Velcheti, Md, MD | Medical Oncology | Jacksonville, FL | $24,825 | $0 |
| Guillermo Garcia-Manero, M.d, M.D | Medical Oncology | Houston, TX | $23,566 | $0 |
| Amado Zurita-Saavedra, M.d, M.D | Medical Oncology | Houston, TX | $22,917 | $0 |
| Robert Haddad, Md, MD | Medical Oncology | Boston, MA | $22,053 | $0 |
| David Peura, M.d, M.D | Gastroenterology | Charlottesville, VA | $21,203 | $0 |
| Susan O'brien, M.d, M.D | Medical Oncology | Orange, CA | $19,684 | $0 |
| William Wierda, M.d., Phd, M.D., PHD | Hematology & Oncology | Houston, TX | $19,287 | $0 |
| Dareen Siri, M.d, M.D | Allergy & Immunology | Normal, IL | $16,728 | $0 |
| Dr. Nitin Jain, Md, MD | Internal Medicine | Houston, TX | $16,558 | $0 |
| Mr. Gary Gross, Md, MD | Allergy | Dallas, TX | $14,187 | $0 |
| George Han, Md, Phd, MD, PHD | Dermatology | New York, NY | $13,200 | $0 |
| Marina Konopleva, M.d. Phd, M.D. PHD | Hematology & Oncology | Houston, TX | $12,926 | $0 |
| Nathan Fowler, M.d, M.D | Hematology & Oncology | Houston, TX | $12,700 | $0 |
Ad
Top Products
- Fluticasone Salmeterol $18.9M
- NOREPINEPHRINE BITARTRATE $2.8M
Associated Products (26)
- Fluticasone Salmeterol $24.0M
- Epinephrine $3.8M
- NOREPINEPHRINE BITARTRATE $2.8M
- Morphine Sulfate ER $1.3M
- Fentanyl Citrate $1.3M
- MORPHINE SULFATE $1.2M
- Mercaptopurine $1.2M
- Phenobarbital $1.1M
- Colchicine $522,445
- Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate $477,331
- Phenylephrine Hydrochloride $388,249
- Vigabatrin $318,071
- Mitigare $293,978
- Oxycodone hydrochloride $265,769
- Ryaltris $255,921
- Buprenorphine HCL $224,724
- Dasatinib $220,046
- Morphine Sulfate $183,420
- Kloxxado $182,687
- COLCHICINE $78,276
- Hydromorphone Hydrochloride $76,797
- Fluticasone Propionate and Salmeterol Xinafoate Dry Powder Inhaler $53,742
- Labetalol HCL in Sodium Chloride $50,931
- Abiraterone $34,599
- Lenalidomide $34,583
- COMBOGESIC IV $22,142
Payment Categories
- Food & Beverage $410,340
- Consulting $3.0M
- Travel & Lodging $521,705
- Research $31.5M
About Hikma Pharmaceuticals USA
Hikma Pharmaceuticals USA has made $35.9M in payments to 11,850 healthcare providers, recorded across 26,231 transactions in the CMS Open Payments database. In 2024, the company paid $942,317. The top product by payment volume is Fluticasone Salmeterol ($18.9M).
Payments were distributed across 160 medical specialties. The top specialty by payment amount is Internal Medicine ($472,834 to 1,874 doctors).
Payment categories include: Food & Beverage ($410,340), Consulting ($3.0M), Research ($31.5M), Travel & Lodging ($521,705).
Hikma Pharmaceuticals USA is associated with 26 products in the CMS Open Payments database, including Fluticasone Salmeterol, Epinephrine, and NOREPINEPHRINE BITARTRATE.